From Old Competence Destruction to New Competence Access: Evidence from the Comparison of Two Discontinuities in Anticancer Drug Discovery
暂无分享,去创建一个
[1] R. Colwell. Fulfilling the promise of biotechnology. , 2002, Biotechnology advances.
[2] Chronic Disease Division. Cancer facts and figures , 2010 .
[3] J. Drews. Into the 21st Century , 1993, Bio/Technology.
[4] H. P. Lang,et al. Drug Discovery And Development- Technology In Transition , 2009 .
[5] Wendy K. Smith,et al. A Structural Approach to Assessing Innovation: Construct Development of Innovation Locus, Type, and Characteristics , 2002, Manag. Sci..
[6] Nelson Phillips,et al. Technology and Organization: Essays in Honour of Joan Woodward , 2010 .
[7] Sarah Kaplan,et al. Entrepreneurship and the Construction of Value in Biotechnology , 2008 .
[8] P. Tyle,et al. Monoclonal antibodies, immunoconjugates, and liposomes as targeted therapeutic systems. , 1990, Targeted diagnosis and therapy.
[9] Constance E. Helfat,et al. The birth of capabilities: market entry and the importance of pre-history , 2002 .
[10] Gino Cattani,et al. Preadaptation, Firm Heterogeneity, and Technological Performance: A Study on the Evolution of Fiber Optics, 1970–1995 , 2005, Organ. Sci..
[11] J. Tilton. International diffusion of technology : the case of semiconductors , 1971 .
[12] P. Tyle,et al. Targeted therapeutic systems , 1990 .
[13] P. Schoemaker,et al. Strategic assets and organizational rent , 1993 .
[14] F. Rothaermel. Incumbent's advantage through exploiting complementary assets via interfirm cooperation , 2001 .
[15] David C. Mowery,et al. Paths of Innovation: Technological Change in 20th-Century America , 1998 .
[16] D. B. Montgomery,et al. First‐mover advantages , 1988 .
[17] David E. Golan,et al. Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.
[18] M. Hannan,et al. Structural Inertia and Organizational Change , 1984 .
[19] R. Slater,et al. Magic cancer bullet : how a tiny orange pill is rewriting medical history , 2003 .
[20] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[21] Rebecca Henderson,et al. DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY , 2004 .
[22] Karel Cool,et al. Asset stock accumulation and sustainability of competitive advantage , 1989 .
[23] Charles Williams,et al. Focusing Firm Evolution: The Impact of Information Infrastructure on Market Entry by U.S. Telecommunications Companies, 1984 - 1998 , 2004, Manag. Sci..
[24] Gary Walsh,et al. Biopharmaceuticals: Biochemistry and Biotechnology , 1998 .
[25] J. Barney. Firm Resources and Sustained Competitive Advantage , 1991 .
[26] J. P. Eggers,et al. Cognition and Renewal: Comparing CEO and Organizational Effects on Incumbent Adaptation to Technical Change , 2009, Organ. Sci..
[27] R. Rumelt. Theory, Strategy, and Entrepreneurship , 2005 .
[28] Constance E. Helfat,et al. Strategic Renewal of Organizations , 2009, Organ. Sci..
[29] W. S. Comanor,et al. Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.
[30] Phanish Puranam,et al. Integrating Acquired Capabilities: When Structural Integration is (Un)Necessary , 2005 .
[31] Cynthia A. Montgomery,et al. Diversification, Ricardian rents, and Tobin's q , 1988 .
[32] Mary Tripsas. Unraveling The Process Of Creative Destruction: Complementary Assets And Incumbent Survival In The Typesetter Industry , 1997 .
[33] Clayton M. Christensen. The Innovator's Dilemma: The Revolutionary Book That Will Change the Way You Do Business , 2011 .
[34] Robert J. Moore,et al. A chronology of medicine and related sciences , 1997 .
[35] R. Katila,et al. Where do resources come from? The role of idiosyncratic situations , 2004 .
[36] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[37] R. Bazell. Her-2: the making of herceptin, a revolutionary treatment for breast cancer , 1998 .
[38] D. Teece. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .
[39] W. Mitchell. Dual clocks: Entry order influences on incumbent and newcomer market share and survival when specialized assets retain their value , 1991 .
[40] M. Tushman,et al. Technological Discontinuities and Organizational Environments , 1986 .
[41] E. Penrose. The theory of the growth of the firm twenty-five years after , 1960 .
[42] M. Lourdes Sosa,et al. Application-Specific R&D Capabilities and the Advantage of Incumbents: Evidence from the Anticancer Drug Market , 2009, Manag. Sci..
[43] Boris Groysberg,et al. Can They Take It With Them? The Portability of Star Knowledge Workers' Performance , 2004, Manag. Sci..
[44] Anita M. McGahan,et al. Business strategy over the industry life cycle , 2004 .
[45] B. Wernerfelt,et al. A Resource-Based View of the Firm , 1984 .
[46] B. Chabner,et al. Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.
[47] Jesper B. Sørensen,et al. Aging, Obsolescence, and Organizational Innovation , 2000 .
[48] J. Barney. Strategic Factor Markets: Expectations, Luck, and Business Strategy , 1986 .
[49] Maryann P. Feldman,et al. The Locational Dynamics of the U.S. Biotech Industry: Knowledge Externalities and the Anchor Hypothesis , 2005 .
[50] Sendil K. Ethiraj,et al. Where Do Capabilities Come from and How Do They Matter? A Study in the Software Services Industry , 2005 .
[51] Samuel B. Bacharach,et al. Research in the Sociology of Organization. , 1994 .